Monitoring and oversight are now scaled based on the actual risks of a trial. Low-risk aspects should not be overburdened with unnecessary bureaucracy.
E6(R3) emphasizes building quality into the trial design from the start, rather than relying on retrospective checking.
The International Council for Harmonisation (ICH) recently finalized the guideline, which entered into force in July 2025. This update represents a major shift toward digital-first, risk-proportional clinical research.
For the first time, the guideline explicitly addresses digital tools, wearables, and the "chain of custody" for digital data to ensure traceability and reproducibility.
